M. Sravani, P. Sai Lakshmi, K. Amuktha Reddy, Naga Deepthi N, Uday Sasi Kiran Kantheti
M. Sravani1*, P. Sai Lakshmi1, K. Amuktha Reddy2, Naga Deepthi N3, Uday Sasi Kiran Kantheti4
1 Dept. of Pharmaceutical Chemistry, JNTU-OTRI, Anantapur. Andhra Pradesh, India.
2 Dept. of Pharmaceutical Analysis, JNTU-OTRI, Anantapur. Andhra Pradesh, India.
3 Dept. of Pharmaceutics, PRRM College of Pharmacy, Andhra Pradesh, India.
4Dept. of Pharmacology, Royal College of Pharmacy and Health Sciences, Berhampur, Odisha.
. *Corresponding Author
Volume - 6,
Issue - 1,
Year - 2013
Alzheimer's disease is characterized by loss of neurons and synapses in the cerebral cortex and certain sub cortical regions. The earliest observable symptoms are often mistakenly thought to be 'age-related' concerns, or manifestations of stress. As the disease advances, symptoms include confusion, irritability and aggression, long-term memory loss. Two drugs specifically approved for treating Alzheimer's disease were Tacrine and Donezepil. Tacrine mainly inhibit the histamine-N-methyltransferase protein which block the histamine transmission. Donepezil inhibit the acetyl cholinesterase which degrades the acetylcholine transmitter. In this study, computational methods are used to design novel tacrine and donepezil derivatives and evaluated them for interaction with the Histamine-N-methyltransferase protein and acetyl cholinesterase protein respectively through insilico analysis by using Hyperchem 8.0, Gold 3.01 docking software. The result of the docking studies shows that ligands of T3 and D3 with R - CH2CH3 are having highest binding affinity.
Cite this article:
M. Sravani, P. Sai Lakshmi, K. Amuktha Reddy, Naga Deepthi N, Uday Sasi Kiran Kantheti. Insilico Analysis and Docking of Tacrine and Donepezil Derivatives Targeting Histamine-N-Methyltransferase and Acetyl Cholinesterase Protein Respectively for Alzheimer's Disease. Research J. Pharm. and Tech. 6(1): Jan. 2013; Page 86-89
Parkinson J. An essay on the shaking palsy. Journal
Clin Neurosi. 14 (2); 1984:
Bar beau A. Manganese
and extra pyramidal disorders (a critical review and tribute to Dr. George C.
Cotzias). Journal of Neurotoxicology.
5(1); 1988: 13-35.
Ozelius L, Senthil
G, Lipton R, Soto-Valencia J, Risch N,
Bressman S. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. New England Journal of Medicine. 354
(4); 1985: 424-5.
M.K. York, H.S.
Levin, R.J. Grossman, W.J. Hamilton. Neuropsychological outcome following unilateral
pallidotomy. Journal of
Brain. 122 (12); 2000:
Alonso D, Dorronsoro
I, Donepezil-tacrine hybrid related derivatives
as new dual binding site inhibitors of AChE. J. Bioorg
Med Chem.13 (24): 1988:
Hornykiewicz. L-DOPA. Biologically inactive amino
acid to a successful therapeutic agent. Institute for Brain Research, University of Vienna.48; 1994:
A Brice. Genetics of Parkinson's disease: LRRK2 on the rise
(Scientific Commentary)". Journal
of Brain. 128
(12); 1987: 2760–2762.
LJ, Goa KL. Addis Review: Galantamine: a review of its use in Alzheimer's
disease. Journal of Drugs.
60 (5); 1984: 1095-1122.
Ghatol SP, Verma S, Agarwal K, Sharon A.
Pharmacophore Distance Mapping and Docking Study of Some Benzimidazole Analogs
as A2A Receptor Antagonists. International
Journal of Pharmaceutical Sciences and Drug Research.2 (1); 2010: 71-77.
Glen RC, Allen SC. Ligand-protein docking:
cancer research at the interface between biology and chemistry. Current Medicinal Chemistry.25; 2003:
Marcel LV, Jason CC, Michael JH,
Christopher WM, Richard DT. Improved protein–ligand docking using GOLD. Proteins: Structure, Function and
Bioinformatics. 52(4); 2003: 609-623.
Meshram RJ, Jangle SN. Molecular docking
and binding energy studies on nuraminidase of h1n1 reveal possible answer to
its resistance for oseltamivir. International
Journal of Drug Discovery. 1(2); 2009: 34-39.
13. M Sravani, N Duganath, Deepak Reddy Gade,
Sandeep Reddy CH. Insilico analysis and docking of imatinib derivatives
targeting BCR-ABL oncoprotein for chronic myeloid leukemia. Asian J. Research Chem. 5(1); 2012: